Serum level of IL13 and expression of BCL2 in Behcet’s disease | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 12, Volume 24, Issue 1, July 2006, Pages 548-555 PDF (522 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2006.17922 | ||
| Authors | ||
| Hanan.M.A Darwish1; Sabila Gomaa Mousa2; Noha Hamdy3; Sahar Zalam4 | ||
| 1Departments of Dermatology and Venereology Faculty of Medicine for girls Al-Azhar University. | ||
| 2General Medicine Faculty of Medicine for girls Al-Azhar University. | ||
| 3Clinical Pathology, Faculty of Medicine for girls Al-Azhar University. | ||
| 4Clinical Pathology,Faculty of Medicine for girls Al-Azhar University. | ||
| Abstract | ||
| Background BD: BCL2 family is a large family of apoptosis regulating proteins consisting of both blockers and promoters of cell death. Immunological processes and a variety of cytokines may play a role in pathophysiological process. Defective regulation of programmed cell death (apoptosis) also play a role in development of Behcet’s disease Objective: To investigate the level of BCL2 and IL13in BD and to determine their to relation monitory disease activity. Patients and methods: This study was conducted on thirty patients (15 active and 15 inactive) and 15-health control, the activity of BD was evaluated according to international study group for BD disease, using ELISA technique for IL 13 and flow cytometry forBCL2. Results: Elevated serum levels of IL13 in patient with active BD than inactive and both had elevated levels than control(P< 0.01) and also the serum levels of Bcl2 was elevated in patient with active BD than inactive and control(P< 0.01). Concolusion: The data suggested that IL13 and BCL2 could be involved in the pathogenesis of BD and its serum levels can be used as marker to monitor disease activity. | ||
|
Statistics Article View: 167 PDF Download: 452 |
||
